Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
OTCMKTS:EKTAY

Elekta Q1 2025 Earnings Report

Elekta logo
$5.23 0.00 (0.00%)
As of 09/30/2026 03:06 PM Eastern
ProfileEarnings HistoryForecast

Elekta EPS Results

Actual EPS
$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$359.76 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elekta Announcement Details

Quarter
Q1 2025
Date
8/28/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Wednesday, November 25, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Earnings Headlines

Elekta data support expanded use of Gamma Knife for multiple brain metastases
September 29 at 3:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-data-support-expanded-use-of-gamma-knife-for-multiple-brain-metastases?utm_source=marketbeat.com&utm_medium=referral
Elekta’s Unity Data Boost Pancreatic Cancer Outcomes as Unity Pro Rolls Out
September 28 at 1:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elektas-unity-data-boost-pancreatic-cancer-outcomes-as-unity-pro-rolls-out?utm_source=marketbeat.com&utm_medium=referral
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 1 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Elekta Broadens Adaptive Radiotherapy Portfolio Across Modalities
September 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-broadens-adaptive-radiotherapy-portfolio-across-modalities?utm_source=marketbeat.com&utm_medium=referral
Insulet (NASDAQ:PODD) & Elekta (OTCMKTS:EKTAY) Critical Comparison
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055432
Elekta AGM Approves Dividend, Board Mandates and New Incentive Plan
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-agm-approves-dividend-board-mandates-and-new-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software. Elekta also provides related services, support and upgrades for healthcare providers.

Founded in 1972 by neurosurgeon Lars Leksell, Elekta has grown into an international supplier serving hospitals, clinics and cancer centers across Europe, North and South America, Asia-Pacific, the Middle East and Africa. The company is headquartered in Stockholm, Sweden, and its shares trade on Nasdaq Stockholm under the symbol “EKTA”; its American depositary shares trade over the counter under the symbol “EKTAY.”

View Elekta Profile
Earnings Tools